Year 2019, Volume 32, Issue 2, Pages 81 - 85 2019-05-31

Outcomes and clinical features of leptomeningeal carcinomatosis: A single center experience

Derya KIVRAK SALIM [1] , Arif Hakan ONDER [2]

22 42

Objective: The aim of this study was to identify the clinical features and prognostic factors of cancer patients with leptomeningeal carcinomatosis (LMC) in a single center. Patients and Methods: Patients 18 and older who had LMC diagnosis between 2013 and 2018 at Medical Oncology Department, Antalya Education and Research Hospital, Health Sciences University were included into the study. Their clinical features, treatment approaches, overall survival, survival after LMC diagnosis and prognostic factors on survival were retrospectively investigated. Results: Sixteen solid cancer patients included in the study. The median time from primary tumor diagnosis to LMC diagnosis was 6 months (range, 1-180 months). The median time from LMC diagnosis to death was 1.5 months (range, 1-14 months). The median overall survival for the entire population was 11 months (95%CI 5.7-16.3). Age (p=0.6), gender (p=0.51), metastases areas (for liver metastases p=0.95, for lung metastases p=0.26, for bone metastases p=0.82), The Eastern Cooperative Oncology Group Performance Status ( ECOG PS) (p=0.18), treatment type of LMC (only radiation therapy (RT) p=0.33; RT followed by intrathecal methotrexate (IT MTX) (p=0.35), RT type (p=0.76) and time from primary tumor diagnosis to LMC diagnosis (p=0.50) did not show prognostic effect on overall survival after LMC diagnosis. Conclusion: Overall survival after LMC diagnosis is too short to see the effect of treatment modalities. Our study did not find any favorable or unfavorable prognostic factor on survival after LMC diagnosis.
Leptomeningeal carcinomatosis, Survival, Prognostic factors
  • 1. Lee SJ, Lee JI, Nam DH, et al. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol 2013; 8:185-91. doi: 10.1097/JTO.0b013e3182773f21.
  • 2. Giglio P, Weinberg JS, Forman AD, Wolff R, Groves MD. Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract. Cancer 2005;103: 2355-62.
  • 3. Kak M, Nanda R, Ramsdale EE, Lukas RV. Treatment of leptomeningeal carcinomatosis: current challenges and future opportunities. J Clin Neurosci 2015; 22:632-7. doi: 10.1016/j.jocn.2014.10.022.
  • 4. Hyun JW, Jeong IH, Joung A, Cho HJ, Kim SH, Kim HJ. Leptomeningeal metastasis: Clinical experience of 519 cases. Eur J Cancer 2016; 56:107-4. doi: 10.1016/j.ejca.2015.12.021
  • 5. Smalley KS, Fedorenko IV, Kenchappa RS, Sahebjam S, Forsyth PA. Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy. Int J Cancer 2016; 139:1195-201.
  • 6. Gwak HS, Joo J, Kim S, et al. Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol 2013; 8: 599-605. doi: 10.1002/ ijc.30147.
  • 7. Palma JA, Fernandez-Torron R, Esteve-Belloch P, et al. Leptomeningeal carcinomatosis: prognostic value of clinical, cerebrospinal fluid, and neuroimaging features. Clin Neurol Neurosurg 2013; 115:19-25.
  • 8. Segura PP, Gil M, Balañá C, et al. Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors. J Neurooncol 2012;109:137-42. doi:10.1016/j. clineuro.2012.03.048.
  • 9. Herrlinger U, Forschler H, Kuker W, et al. Leptomeningealmetastasis: survival and prognostic factors in 155 patients. JNeurol Sci 2004; 223:167e78.
  • 10. Bruna J, González L, Miró J, Velasco R, Gil M, Tortosa A. Leptomeningeal carcinomatosis:prognostic implications of clinical and cerebrospinal fluid features. Cancer 2009; 115:381-9. doi: 10.1002/cncr.24041.
  • 11. Waki F, Ando M, Takashima A, et al. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J Neurooncol 2009; 93:205-12. doi: 10.1007/s11060.008.9758-3.
  • 12. Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM. Leptomeningeal metastases in the MRI era. Neurology 2010;74:1449-54. doi:10.1212/WNL.0b013e3181dc1a69.
  • 13. Du C, Hong R, Shi Y, Yu X, Wang J. Leptomeningeal metastasis from solid tumors: a single center experience in Chinese patients. J Neurooncol 2013; 115: 285-91.doi: 10.1007/s11060.013.1228-x.
  • 14. Passarin MG, Sava T, Furlanetto J, et al. Leptomeningeal metastasis from solid tumors: a diagnostic Leptomeningeal metastasis from solid tumors: a diagnostic and therapeutic challenge. Neurol Sci 2015; 36:117-23. doi: 10.1007/ s10072.014.1881-7.
  • 15. Boogerd W, van den Bent MJ, Koehler PJ, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 2004;40:2726-33.
  • 16. El Shafie RA, Böhm K, Weber D, et al. Outcome and prognostic factors following palliative craniospinal irradiation for leptomeningeal carcinomatosis. Cancer Manag Res 2019;11:789-801. doi: 10.2147/CMAR.S182154.
  • 17. El Shafie RA, Böhm K, Weber D, et al. Palliative radiotherapy for leptomeningeal carcinomatosis-analysis of outcome, prognostic factors, and symptom response. Front Oncol 2019;8:641. doi: 10.3389/fonc.2018.00641.
  • 18. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995;38:51-7.
Primary Language en
Subjects Medicine
Journal Section Original Research
Authors

Author: Derya KIVRAK SALIM (Primary Author)

Author: Arif Hakan ONDER

Bibtex @research article { marumj570913, journal = {Marmara Medical Journal}, issn = {1019-1941}, eissn = {1309-9469}, address = {Marmara University}, year = {2019}, volume = {32}, pages = {81 - 85}, doi = {10.5472/marumj.570913}, title = {Outcomes and clinical features of leptomeningeal carcinomatosis: A single center experience}, key = {cite}, author = {KIVRAK SALIM, Derya and ONDER, Arif Hakan} }
APA KIVRAK SALIM, D , ONDER, A . (2019). Outcomes and clinical features of leptomeningeal carcinomatosis: A single center experience. Marmara Medical Journal, 32 (2), 81-85. DOI: 10.5472/marumj.570913
MLA KIVRAK SALIM, D , ONDER, A . "Outcomes and clinical features of leptomeningeal carcinomatosis: A single center experience". Marmara Medical Journal 32 (2019): 81-85 <http://dergipark.org.tr/marumj/issue/45474/570913>
Chicago KIVRAK SALIM, D , ONDER, A . "Outcomes and clinical features of leptomeningeal carcinomatosis: A single center experience". Marmara Medical Journal 32 (2019): 81-85
RIS TY - JOUR T1 - Outcomes and clinical features of leptomeningeal carcinomatosis: A single center experience AU - Derya KIVRAK SALIM , Arif Hakan ONDER Y1 - 2019 PY - 2019 N1 - doi: 10.5472/marumj.570913 DO - 10.5472/marumj.570913 T2 - Marmara Medical Journal JF - Journal JO - JOR SP - 81 EP - 85 VL - 32 IS - 2 SN - 1019-1941-1309-9469 M3 - doi: 10.5472/marumj.570913 UR - https://doi.org/10.5472/marumj.570913 Y2 - 2019 ER -
EndNote %0 Marmara Medical Journal Outcomes and clinical features of leptomeningeal carcinomatosis: A single center experience %A Derya KIVRAK SALIM , Arif Hakan ONDER %T Outcomes and clinical features of leptomeningeal carcinomatosis: A single center experience %D 2019 %J Marmara Medical Journal %P 1019-1941-1309-9469 %V 32 %N 2 %R doi: 10.5472/marumj.570913 %U 10.5472/marumj.570913
ISNAD KIVRAK SALIM, Derya , ONDER, Arif Hakan . "Outcomes and clinical features of leptomeningeal carcinomatosis: A single center experience". Marmara Medical Journal 32 / 2 (May 2019): 81-85. https://doi.org/10.5472/marumj.570913